Opthea Competitors

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a range of blinding diseases, including age-related macular degeneration, retinal detachment, glaucoma, and inherited retinal disease.

Sensei Biotherapeutics is an immuno-oncology company that is dedicated to understanding and selectively interacting with the tumor microenvironment in order to tilt the immune system against cancer. We are leveraging our TMAb™ platform to develop highly selective therapeutics that have the potential to alter the relationship between host immune cells and cancer so that the tumor is recognized and treated as if it were an infection. Our team is comprised of lifelong learners striving for insight at the intersection of immunology, oncology and biology. We are driven to apply our scientific curiosity to the critical needs faced daily by people who are diagnosed with cancer and the physicians who treat them. We stay humble, always follow the data, and believe that our deep knowledge of cancer biology, the tumor microenvironment, and immunology will lead us to effective therapies.